Search

Displaying results 3341 - 3350 of 10000 in total
  1. Drug

    Betibeglogene autotemcel

    go.drugbank.com/drugs/DB16900
    ApprovedInvestigational

    production (β<sup>0</sup>/β<sup>0</sup>). … [A251770,A251785] Betibeglogene autotemcel was approved by the FDA in August 2022 and is the first ex-vivo lentiviral vector gene therapy available in the U.S. for the treatment of people with β-thalassemia

  2. Drug

    Cediranib

    go.drugbank.com/drugs/DB04849
    Investigational

    The novel indole-ether quinazoline Cediranib is a highly potent (IC<sub>50</sub> &lt; 1 nmol/L) ATP-competitive inhibitor of recombinant KDR tyrosine kinase in vitro. … It is being developed clinically as a once-daily oral therapy for the treatment of cancer.

  3. Drug

    Streptococcus pneumoniae type 8 capsular polysaccharide antigen

    go.drugbank.com/drugs/DB10326
    ApprovedInvestigational

    It is an active immunization for intramuscular or subcutaneous injection against pneumococcal disease such as pneumococcal pneumonia and pneumococcal bacteremia.

    Mixtures: PNEUMOVAX 23 0,5 ML ENJEKSIYONLUK COZELTI ICEREN FLAKON, 1 ADET, Prevnar 20
  4. Drug

    Streptococcus pneumoniae type 11a capsular polysaccharide antigen

    go.drugbank.com/drugs/DB10330
    ApprovedInvestigational

    It is an active immunization for intramuscular or subcutaneous injection against pneumococcal disease such as pneumococcal pneumonia and pneumococcal bacteremia.

    Mixtures: PNEUMOVAX 23 0,5 ML ENJEKSIYONLUK COZELTI ICEREN FLAKON, 1 ADET, Prevnar 20
  5. Drug

    Allogeneic Cardiosphere-Derived Cells

    go.drugbank.com/drugs/DB15744
    Investigational

    Cardiosphere-derived cells (CDCs) are derived from human neonatal heart tissue with a distinct antigenic profile (CD105+, CD45-, and CD90low). They exert their effects by secreting exosomes: nanometer-sized, membrane-bound vesicles used ...

  6. Drug

    Equine Botulinum Neurotoxin E Immune FAB2

    go.drugbank.com/drugs/DB13897
    Approved

    Equine Botulinum Neurotoxin E Immune FAB2 is composed of a mixture of immune globulin fragments purified from plasma of horses that were previously immunized with botulinum toxin serotype E. It is intravenously administered for the treat...

    Mixtures: Bat
  7. Drug

    Equine Botulinum Neurotoxin C Immune FAB2

    go.drugbank.com/drugs/DB13898
    Approved

    Equine Botulinum Neurotoxin C Immune FAB2 is composed of a mixture of immune globulin fragments purified from plasma of horses that were previously immunized with botulinum toxin serotype C. It is intravenously administered for the treat...

    Mixtures: Bat
  8. Drug

    Equine Botulinum Neurotoxin B Immune FAB2

    go.drugbank.com/drugs/DB13903
    Approved

    Equine Botulinum Neurotoxin B Immune FAB2 is composed of a mixture of immune globulin fragments purified from plasma of horses that were previously immunized with botulinum toxin serotype B. It is intravenously administered for the treat...

    Mixtures: Bat
  9. Drug

    Calcitonin gene-related peptide

    go.drugbank.com/drugs/DB06379
    Investigational

    As a potential drug, it has demonstrated in preclinical studies a profile that could make it an ideal anti-asthmatic drug candidate with bronchodilatory, bronchoprotecting and anti-inflammatory properties … The peptide produces multiple biological effects and has both circulatory and neurotransmitter modes of action. In particular, it is a potent endogenous vasodilator.

  10. Drug

    Ibrigampar

    go.drugbank.com/drugs/DB05490
    Investigational

    AMG-131 (T131), an orally-administered therapy, is expected to lower blood glucose in type II diabetic patients by improving the body’s ability to respond to insulin.